Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBITDA (2018 - 2025)

Historic EBITDA for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' EBITDA fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 649.07%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported EBITDA of -$13.4 million as of Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBITDA peaked at $117.3 million during Q4 2022, and registered a low of -$56.3 million during Q1 2021.
  • Moreover, its 5-year median value for EBITDA was -$21.6 million (2022), whereas its average is -$18.0 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' EBITDA plummeted by 47631.18% in 2021, and later skyrocketed by 40351.24% in 2022.
  • Arcturus Therapeutics Holdings' EBITDA (Quarter) stood at -$38.7 million in 2021, then surged by 403.51% to $117.3 million in 2022, then crashed by 109.98% to -$11.7 million in 2023, then plummeted by 156.3% to -$30.0 million in 2024, then surged by 55.18% to -$13.4 million in 2025.
  • Its EBITDA was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.